Category Archives: Invokana

FDA Delays Final OK for Type 2 Drug Empagliflozin

The FDA will delay allowing the type 2 drug empagliflozin to enter the U.S. market until “previously observed deficiencies” at the plant where it is manufactured are fixed.

The delay does not call into question the safety or utility of …

First-World Type 2 Drug Market to Reach $47 Billion by 2022

A Massachusetts-based research firm concludes that the first-world market for type 2 drugs and treatments will increase from $27 billion in sales in 2012 to $47 billion in 2022.

The firm, Decision Resources, says increased sales in the United States, …